Navigation Links
New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth

CHAPEL HILL, N.C., Feb. 5 /PRNewswire/ -- In today's tough economy, maintaining operational efficiencies remains key, even while focusing on strategy and tactics to drive growth and profitability. In an effort to better understand the resources dedicated by biopharmaceutical companies to support marketing operations, a recent benchmark study was conducted by Best Practices, LLC, with insights available in the newly published report, "Benchmarks for Optimizing Marketing Staff Levels to Drive Growth." Data from this study were collected from more than sixty biopharma marketing leaders.

Benchmark data shares insights from a number of critical areas, including:

-- Staffing and productivity levels utilized across healthcare business models

    -- Growth and profit margin levels across biopharma portfolios
    -- Strategic and tactical activities that drive profitability & growth

The metrics shared in this study, segmented across pharma/biotech, medical devices and generic products, were gathered from across the biopharma industry including such companies as Abbott, Amgen, Baxter, Johnson & Johnson, Novartis, Pfizer, Roche, and Sanofi-Aventis.

    Key metrics found in the report include:
    -- Number of Products Supported Per Tactical Marketing FTE
    -- Number of Strategic Marketing FTEs per $100 Million
    -- Time & Activity Benchmarks for Strategic Marketing Staff
    -- Strategic Marketing Staff Benchmarks Across Key Activities
    -- Tactical Marketing Staff Benchmarks Across Key Activities

For more information on this report, contact Ben Gregory at or (919) 767-9160. To access the full report or download a complimentary copy of the report summary, go to


Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.

SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
2. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
3. New Study Provides Benchmarks for Winning Brand Team Management
4. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
5. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
8. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
9. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
10. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
11. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Post Your Comments:
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
(Date:10/23/2015)... Research and Markets ( ) has ... Biometrics Market 2015-2019" report to their offering. ... global voice recognition biometrics market to grow at a ... --> --> The report, Global Voice ... an in-depth market analysis with inputs from industry experts. ...
Breaking Biology News(10 mins):